Tumour angiogenesis is reduced in the Tc1 mouse model of Down Syndrome

[1]  鮫島 浩,et al.  Population-based study からみた神経予後不良因子の検討 , 2009 .

[2]  George Q. Daley,et al.  Down syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1 , 2009, Nature.

[3]  J. Norman,et al.  Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors , 2009, Nature Medicine.

[4]  Angelika Amon,et al.  Aneuploidy Affects Proliferation and Spontaneous Immortalization in Mammalian Cells , 2008, Science.

[5]  Dov Stekel,et al.  The University of Birmingham ( Live System ) A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes , 2016 .

[6]  E. Dejana,et al.  Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. , 2008, Blood.

[7]  Michael C. Ostrowski,et al.  Trisomy represses ApcMin-mediated tumours in mouse models of Down’s syndrome , 2008, Nature.

[8]  M. Iruela-Arispe,et al.  ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2 , 2006, The EMBO journal.

[9]  J. Norman,et al.  VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. , 2006, Blood.

[10]  F. Orsenigo,et al.  Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments , 2006, The Journal of cell biology.

[11]  Y-j Liu,et al.  Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively , 2006, Oncogene.

[12]  K. Davies,et al.  Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product Calcipressin 1 (or RCAN1) in disease , 2005, Cellular and Molecular Life Sciences CMLS.

[13]  K. Matsushima,et al.  ADAMTS-1 is involved in normal follicular development, ovulatory process and organization of the medullary vascular network in the ovary. , 2005, Journal of molecular endocrinology.

[14]  Dean Nizetic,et al.  An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes , 2005, Science.

[15]  P. Kelly,et al.  DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. , 2005, Molecular biology of the cell.

[16]  D. Hicklin,et al.  Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice , 2004, Cancer Research.

[17]  Takahide Kohro,et al.  Vascular Endothelial Growth Factor- and Thrombin-induced Termination Factor, Down Syndrome Critical Region-1, Attenuates Endothelial Cell Proliferation and Angiogenesis*♦ , 2004, Journal of Biological Chemistry.

[18]  Masashi Iizuka,et al.  Down Syndrome Candidate Region 1,a Downstream Target of VEGF, Participa tes in Endothelial Cell Migration and Angiogenesis , 2004, Journal of Vascular Research.

[19]  M. Iruela-Arispe,et al.  ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165* , 2003, Journal of Biological Chemistry.

[20]  I. Kola,et al.  ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. , 2003, Human molecular genetics.

[21]  S. Rasmussen,et al.  Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study , 2002, The Lancet.

[22]  H. Hasle.  Pattern of malignant disorders in individuals with Down's syndrome. , 2001, The Lancet. Oncology.

[23]  M. Aurrand-Lions,et al.  JAM-2, a Novel Immunoglobulin Superfamily Molecule, Expressed by Endothelial and Lymphatic Cells* , 2001, The Journal of Biological Chemistry.

[24]  C. Benz,et al.  A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes. , 2000, Molecular biology of the cell.

[25]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[26]  M. Nishi,et al.  A tumor profile in Down syndrome. , 1998, American journal of medical genetics.

[27]  S. Mckercher,et al.  Defective trophoblast function in mice with a targeted mutation of Ets2. , 1998, Genes & development.

[28]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[29]  I. Hart,et al.  Factors influencing blood supply in wound granuloma quantitated by a new in vivo technique. , 1989, Cancer research.

[30]  F. Cavalli,et al.  Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. , 2004, Nucleic acids research.

[31]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. , 2002, Nature medicine.